... what do they say?

Yes.

Uh, our, um, recommendations, uh, uh, have the aim of, uh, integrating B-cells, depleting therapies, complement inhibitors, FC, neonatal receptor inhibitors, uh, in the general management of myasthenia gravis.

And, uh, um, its use in persistent, active or refractory disease, or in patients intolerance of immunosuppress- immunosuppress- uh, suppression or with severe adverse events.

Of course, therapy escalation must be guided by disease severity, and treatment choices, uh, by antibody profile, as we know, uh, that by the disease pattern.

Uh, y- One thing is to treat a chronic, even progressive disease, or a disease with very frequent, uh, severe relapses.

But also by patients characteristics like age and comorbidities.

... to add from the Italian point of view?